Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1
Jing Fang(Wuhan Puai Hospital), Daniel T. Starczynowski(Cincinnati Children's Hospital Medical Center), Garrett W. Rhyasen(AstraZeneca (United States)), Carmela Rigolino(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Mark Wunderlich(Cincinnati Children's Hospital Medical Center), Maria Cuzzola(University of Messina), Lyndsey Bolanos(Cincinnati Children's Hospital Medical Center), Jacqueline Cloos(Vrije Universiteit Amsterdam), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Melinda E. Varney(Cincinnati Children's Hospital Medical Center), Esther N. Oliva(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), James C. Mulloy(Cincinnati Children's Hospital Medical Center), Susumu Goyama(The University of Tokyo), Gerrit Jansen(Amsterdam UMC Location VUmc)
Cited by 103
Related Papers
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism
|Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease|2002|430